117 results match your criteria Issues in Emerging Health Technologies [Journal]


Laparoscopic diaphragm pacing for tetraplegia.

Issues Emerg Health Technol 2009 Sep(115):1-5

(1) The NeuRx DPS is a laparoscopically implanted device that provides ventilatory support. (2) This device stimulates the diaphragm muscle, rather than the phrenic nerve, and is intended to lead to less risk of nerve damage than other therapies.(3) This technology provides an alternative to mechanical ventilation, and allows patients to increase day-to-day freedom and minimize the risk of respiratory infection. Read More

View Article

Download full-text PDF

Source
September 2009
4 Reads

Implantable hemodynamic monitoring (the Chronicle IHM system): remote telemonitoring for patients with heart failure.

Authors:
C Ho

Issues Emerg Health Technol 2008 Jan(111):1-4

(1) Remote monitoring for ambulatory heart failure patients uses an implantable device to record hemodynamic data and transmit it to a central server for continuous assessment. (2) Preliminary evidence from observational studies suggests a potential for reducing hospitalizations with the use of right ventricle implantable hemodynamic monitoring (IHM). However, although a multicentre, randomized controlled trial (COMPASS-HF) showed a reduction in hospitalizations in the IHM group the results were not statistically significant and the US Food and Drug Administration panel concluded the trial failed to meet its primary efficacy endpoint. Read More

View Article

Download full-text PDF

Source
January 2008
6 Reads

Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.

Authors:
V Chatsis

Issues Emerg Health Technol 2008 Feb(112):1-6

View Article

Download full-text PDF

Source
February 2008
5 Reads

Continuous erythropoietin receptor activator (Mircera) for renal anemia.

Authors:
L McGahan

Issues Emerg Health Technol 2008 Feb(113):1-6

(1) Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). Read More

View Article

Download full-text PDF

Source
February 2008
6 Reads

Milnacipran for fibromyalgia.

Authors:
J Dempsey

Issues Emerg Health Technol 2008 Feb(114):1-4

(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Read More

View Article

Download full-text PDF

Source
February 2008
4 Reads

Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

Authors:
S Ndegwa

Issues Emerg Health Technol 2007 Dec(110):1-8

(1) Maraviroc belongs to a new class of antiretroviral drugs designed to block entry of HIV-1 into CD4+ T-cells via the CCR5 coreceptor. It is indicated for combination therapy in treatment-experienced adults infected with CCR5-tropic HIV-1 that is resistant to multiple antiretroviral agents. (2) Results from two randomized controlled trials (RCTs) indicate that in treatment experienced patients, maraviroc, combined with optimized background therapy (OBT), significantly decreases the level of HIV-1 RNA in the blood (viral load) when compared with OBT alone. Read More

View Article

Download full-text PDF

Source
December 2007
1 Read

Human papillomavirus (HPV) vaccines: a Canadian update.

Issues Emerg Health Technol 2007 Dec(109):1-8

A common sexually transmitted infection, human papillomavirus (HPV) has been linked to the development of cervical, anogenital, and head and neck cancers and genital warts. (2) Several randomized controlled trials have explored the efficacy and safety of two vaccines for primary prevention of infection by HPV types 16 and 18, those most commonly implicated in the development of cervical cancer. (3) An HPV vaccine, Gardasil, was approved in Canada in 2006, and a second vaccine, Cervarix, is undergoing Health Canada review. Read More

View Article

Download full-text PDF

Source
December 2007
6 Reads

Portable home hemodialysis for kidney failure.

Authors:
A Scott

Issues Emerg Health Technol 2007 Nov(108):1-4

(1) Home hemodialysis has been in limited use in Canada for some time. Newer, portable hemodialysis machines that are easier for patients to operate may encourage the uptake of this technology. (2) One portable system is already available in the US. Read More

View Article

Download full-text PDF

Source
November 2007
22 Reads

Grazax: an oral vaccine for the treatment of grass pollen allergy (hay fever).

Authors:
C Allison J Fraser

Issues Emerg Health Technol 2007 Nov(107):1-4

Grazax is a self-administered, once-daily, tablet-based vaccine that offers an alternative to allergy shots for adults with grass pollen allergy (hay fever). (2) Evidence from three randomized controlled trials indicates modest improvements in hay fever symptoms, with reduced use of medication to control symptoms (rescue medication use) in adults who took Grazax compared with placebo. No studies have compared Grazax with injection-based allergen immunotherapy. Read More

View Article

Download full-text PDF

Source
November 2007
4 Reads

Capsule colonoscopy: PillCam Colon.

Authors:
K Tran

Issues Emerg Health Technol 2007 Oct(106):1-4

(1) The PillCam Colon capsule is an ingestible miniature camera that captures images of the colon's inner lining. (2) There is limited evidence on the use of this technology in imaging the colon. Two small, methodologically flawed pilot studies found that for patients with positive findings (i. Read More

View Article

Download full-text PDF

Source
October 2007
4 Reads

Subcutaneous open-loop insulin delivery for type 1 diabetes: Paradigm Real-Time System.

Authors:
S L Pohar

Issues Emerg Health Technol 2007 Oct(105):1-6

(1) An open-loop insulin delivery system combines an external insulin pump with continuous monitoring of glucose levels via a subcutaneous sensor. The sensor communicates glucose readings to the pump using a radio transmitter. (2) In four small, comparative studies, adults and children with poorly controlled type 1 diabetes who were randomized to use the Paradigm Real-Time System had clinically important improvements in A1c (a measure of average glycemic control over the previous three months) compared to baseline. Read More

View Article

Download full-text PDF

Source
October 2007
5 Reads

Pharmacogenomics and warfarin therapy.

Authors:
S Ndegwa

Issues Emerg Health Technol 2007 Oct(104):1-8

(1) Dosing algorithms tailored to individual genetic, demographic, and clinical factors may minimize the risk for bleeding during the initiation of warfarin therapy. (2) Pharmacogenomic testing should be used in addition to (rather than replacing) routine International Normalized Ratio (INR) monitoring. (3) Prospective studies are needed to determine whether pharmacogenomic testing improves patient outcomes, identify which subgroups of patients may benefit, and clarify the risks and costs associated with the use of these tests. Read More

View Article

Download full-text PDF

Source
October 2007
4 Reads

Nicotine vaccines for smoking cessation.

Issues Emerg Health Technol 2007 Sep(103):1-4

(1) Cigarette smoking is the leading cause of preventable disease and death in the world. (2) Nicotine vaccines produce antibodies that bind nicotine, the chief addictive agent in cigarettes, and prevent it from entering the brain. (3) Early trials suggest nicotine vaccines are safe and well tolerated, but the duration of effect is unclear, and immunological response varies across recipients. Read More

View Article

Download full-text PDF

Source
September 2007
2 Reads

Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.

Authors:
C Allison

Issues Emerg Health Technol 2007 Sep(102):1-6

(1) Microspheres containing radioactive yttrium-90 (90Y) are infused into the hepatic artery. These deliver high doses of ionizing radiation to inoperable hepatocellular carcinoma, the most common type of primary liver cancer. (2) Limited evidence from several case series indicates that palliative therapy with 90Y microspheres may reduce tumour size and increase survival time. Read More

View Article

Download full-text PDF

Source
September 2007
6 Reads

Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.

Authors:
I McKarney

Issues Emerg Health Technol 2007 Sep(101):1-4

(1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express prostatic acid phosphatase (PAP) antigen. (2) Sipuleucel-T demonstrated a survival benefit in men with advanced androgen-independent prostate cancer (AIPC), although this preliminary finding requires confirmation in larger trials. (3) Mild to moderate myalgia, chills, fever, and tremor are the most commonly reported adverse events for patients receiving sipuleucel-T. Read More

View Article

Download full-text PDF

Source
September 2007
7 Reads

Nuchal translucency measurement in first trimester Down syndrome screening.

Authors:
A Scott

Issues Emerg Health Technol 2007 Jun(100):1-6

(1) Approximately three in every four fetuses with Down syndrome have increased nuchal translucency (NT), which is a larger than normal build-up of fluid at the back of the neck. (2) The ultrasound measurement of NT between 11 and 14 weeks' gestation, in combination with the mother's age and the levels of placental biochemical markers in her blood, can be used to detect approximately 84% of fetuses with Down syndrome. (3) The accuracy of NT measurement is affected by fetal position, measurement technique, the type of risk-calculation software used, and the sonographer's experience and technical expertise. Read More

View Article

Download full-text PDF

Source
June 2007
1 Read

Ranolazine (Ranexa) for chronic stable angina.

Authors:
S Ndegwa

Issues Emerg Health Technol 2007 Jun(99):1-6

(1) Ranolazine-- an adjunctive treatment to beta-blockers, calcium channel blockers, or long-acting nitrates-- is indicated for patients with chronic stable angina who have not responded to standard anti-anginal therapy. (2) In three randomized controlled trials (RCTs), ranolazine, in combination with standard anti-anginal medications, led to modest but statistically significant improvements in exercise duration, and reductions in the frequency of angina episodes and nitroglycerin consumption, when compared to standard anti-anginal medications only. The clinical significance of these improvements is unknown. Read More

View Article

Download full-text PDF

Source
June 2007
5 Reads

Intra-articular hyaluronic acid (viscosupplementation) for hip osteoarthritis.

Authors:
S Dagenais

Issues Emerg Health Technol 2007 May(98):1-4

In viscosupplementation, a glycosaminoglycan called hyaluronic acid (HA) is administered via intra-articular injection to patients with osteoarthritis (OA). Two systematic reviews found that HA for hip OA may relieve pain and improve function. Randomized controlled trials had differing results. Read More

View Article

Download full-text PDF

Source
May 2007
2 Reads

Obstructive sleep apnea: a palatable treatment option?

Authors:
C Allison

Issues Emerg Health Technol 2007 Jan(97):1-4

(1) The Pillar(R) Palatal Implant System consists of three polyester threads that are permanently implanted in the palate (the roof of the mouth) to reduce airway obstruction in individuals with mild to moderate obstructive sleep apnea (OSA) and snoring. (2) Three small, non-randomized uncontrolled trials reported a moderate reduction in the number of breathing interruptions during sleep, three to six months following palatal implant insertion. Statistically significant improvements in daytime sleepiness and snoring intensity were also reported. Read More

View Article

Download full-text PDF

Source
January 2007
2 Reads

Extracorporeal shock wave treatment for chronic rotator cuff tendonitis (shoulder pain).

Authors:
C Ho

Issues Emerg Health Technol 2007 Jan(96 (part 3)):1-4

(1) Electrohydraulic, electromagnetic, or piezoelectric devices are used to translate energy into acoustic waves during extracorporeal shock wave treatment (ESWT) for chronic rotator cuff tendonitis (shoulder pain). The acoustic waves may help to accelerate the healing process of chronic rotator cuff tendonitis via an unknown mechanism. (2) ESWT, which is performed as an outpatient procedure, is intended to alleviate the pain due to chronic rotator cuff tendonitis. Read More

View Article

Download full-text PDF

Source
January 2007
4 Reads

Extracorporeal shock wave treatment for chronic lateral epicondylitis (tennis elbow).

Authors:
C Ho

Issues Emerg Health Technol 2007 Jan(96 (part 2)):1-4

(1) Electrohydraulic, electromagnetic, or piezoelectric devices are used to translate energy into acoustic waves during extracorporeal shock wave treatment (ESWT) for chronic lateral epicondylitis (CLE) of the elbow (elbow tendonitis or tennis elbow). These waves may help to accelerate the healing process via an unknown mechanism. (2) Results from randomized controlled trials have been conflicting. Read More

View Article

Download full-text PDF

Source
January 2007
4 Reads

Extracorporeal shock wave treatment for chronic plantar fasciitis (heel pain).

Authors:
C Ho

Issues Emerg Health Technol 2007 Jan(96 (part 1)):1-4

(1) Electrohydraulic, electromagnetic, or piezoelectric devices are used to translate energy into acoustic waves during extracorporeal shock wave treatment (ESWT) for chronic plantar fasciitis (or heel pain). These waves may help to accelerate the healing process via an unknown mechanism. (2) ESWT, which is performed as an outpatient procedure, is intended to alleviate the pain due to chronic plantar fasciitis. Read More

View Article

Download full-text PDF

Source
January 2007
2 Reads

Photoselective vaporization for benign prostatic hyperplasia.

Issues Emerg Health Technol 2006 Dec(95):1-4

(1) In photoselective vaporization of the prostate (PVP) for benign prostatic hyperplasia (BPH), laser energy is used to vaporize prostatic tissue rapidly and bloodlessly. (2) Studies suggest that PVP performs well in the short term. (3) Randomized controlled trials (RCTs) and longterm follow-up are required to determine PVP's place in the management of BPH. Read More

View Article

Download full-text PDF

Source
December 2006
3 Reads

Intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis.

Authors:
S Dagenais

Issues Emerg Health Technol 2006 Nov(94):1-4

(1) In viscosupplementation, a glycosaminoglycan (GAG) called hyaluronic acid (HA) is administered via intra-articular (IA) injection for patients with knee osteoarthritis (OA). (2) Evidence suggests modest short-term reductions in pain and improvements in function, and no superiority among HA products. (3) Adverse events are rare, benign, temporary, and likely associated with the IA injection. Read More

View Article

Download full-text PDF

Source
November 2006
5 Reads

Hot techniques for tonsillectomy.

Authors:
A Scott

Issues Emerg Health Technol 2006 Nov(93):1-6

Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada.

(1) Some patients experience pain and bleeding after a standard or extracapsular tonsillectomy. (2) Evidence suggests that none of the hot tonsillectomy techniques offers concurrent reductions in intra- and post-operative bleeding and pain, compared with traditional cold-steel dissection with packs or ties. (3) Little information is available on the cost effectiveness of the hot techniques. Read More

View Article

Download full-text PDF

Source
November 2006
3 Reads

Open magnetic resonance imaging (MRI) scanners.

Authors:
D Hailey

Issues Emerg Health Technol 2006 Nov(92):1-4

Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada.

(1) In most MRI scanners, the patient examination table fits inside a long cylindrical tube. Large patients cannot be accommodated, and some persons experience claustrophobic reactions. Open MRI systems, in which the patient is placed between two plates, overcome these disadvantages. Read More

View Article

Download full-text PDF

Source
November 2006
3 Reads

Digital mammography: an update.

Authors:
D Hailey

Issues Emerg Health Technol 2006 Oct(91):1-4

(1) Digital mammography can improve breast-image quality and storage through the digital capture of x-ray images. (2) Large comparative studies indicate that the overall accuracy of full-field digital mammography (FFDM) is similar to that of conventional filmscreen mammography (FSM). (3) Recent evidence suggests that FFDM is more accurate than FSM for diagnosing cancer in women younger than 50 years, those with dense breasts, and pre- or peri-menopausal women. Read More

View Article

Download full-text PDF

Source
October 2006
9 Reads

Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis.

Issues Emerg Health Technol 2006 Sep(90):1-4

(1) Liver fibrosis is associated with significant morbidity and mortality. The major cause is hepatitis C, which affects 240,000 Canadians. (2) Assessing the degree of liver fibrosis is critical to its management. Read More

View Article

Download full-text PDF

Source
September 2006
7 Reads

Rituximab for rheumatoid arthritis.

Issues Emerg Health Technol 2006 Sep(89):1-4

(1) Rituximab (RTX), a monoclonal antibody, selectively targets CD20+ B-cells that are implicated in the pathogenesis of rheumatoid arthritis (RA). (2) The use of RTX with methotrexate (MTX) results in statistically significant clinical improvements among RA patients who have an inadequate response to standard therapies, when compared to the use of MTX alone. (3) The optimal dose, duration of treatment or retreatment, long-term efficacy and safety, and placement of RTX in RA treatment algorithms need to be further investigated. Read More

View Article

Download full-text PDF

Source
September 2006
3 Reads

Tacrolimus for Crohn's disease.

Authors:
Ruddock B

Issues Emerg Health Technol 2006 Sep(88):1-4

(1) Tacrolimus (FK-506) is an immunosuppressant that is being investigated for use in patients with Crohn's disease, mainly in those with refractory illness and fistulizing patterns of the disease. (2) Evidence from a small, randomized controlled trial indicates that, compared with placebo, tacrolimus is associated with higher rates of improvement and similar rates of remission in those with fistulizing patterns of disease. (3) Nephrotoxicity, which has been reported with the use of tacrolimus in clinical trials, seems to improve with dose reduction, but may be associated with irreversible histologic changes. Read More

View Article

Download full-text PDF

Source
September 2006
4 Reads

Febuxostat for prevention of gout attacks.

Authors:
S Pohar G Murphy

Issues Emerg Health Technol 2006 Aug(87):1-4

(1) Febuxostat is a selective inhibitor of xanthine oxidase. Its use in the management of hyperuricemia and gout is being studied. (2) In a 52-week, phase III randomized clinical trial, febuxostat was superior to allopurinol for lowering uric acid levels. Read More

View Article

Download full-text PDF

Source
August 2006
5 Reads

BpTRU(tm) blood pressure monitor for use in a physician's office.

Authors:
C Allison

Issues Emerg Health Technol 2006 Aug(86):1-4

The BpTRU(tm) is an automated device that takes serial blood pressure (BP) measurements in a physician's office. (1) Preliminary data from non-randomized, uncontrolled trials suggest that the average of five BpTRU measurements, taken while the patient is alone, more reliably reflects "resting" BP compared to manual measurements taken with a stethoscope and sphygmomanometer. (2) BpTRU helps reduce the overestimation of BP due to improper measurement technique, or due to a patient's anxiety in a physician's presence ("white coat" effect). Read More

View Article

Download full-text PDF

Source
August 2006
7 Reads

Accommodative intraocular lenses for age-related cataracts.

Authors:
A Scott

Issues Emerg Health Technol 2006 Aug(85):1-6

The standard intraocular lens (IOL) that is used to replace a cataractous lens cannot change focus from distant to near objects, so most patients need glasses for near vision after cataract surgery. Limited evidence suggests that accommodative IOLs provide better near vision than monofocal IOLs, but not better than multifocal IOLs. Long-term follow-up is needed to confirm patient outcomes, and determine whether the benefits justify the additional cost. Read More

View Article

Download full-text PDF

Source
August 2006
2 Reads

Chondroitin sulfate for interstitial cystitis.

Issues Emerg Health Technol 2006 May(84):1-4

(1) Chondroitin sulfate solution 2.0% is a glycosaminoglycan (GAG) replenishment therapy instilled into the bladder of GAG-deficient patients with interstitial cystitis (IC). (2) Two non-randomized, uncontrolled pilot studies report improvements in patient-reported symptoms after the use of chondroitin sulfate for one year. Read More

View Article

Download full-text PDF

Source
May 2006
3 Reads

Radiofrequency neurotomy for lumbar pain.

Issues Emerg Health Technol 2006 May(83):1-4

(1) Chronic lumbar (lower back) pain, which affects many Canadians, imposes a large economic burden. (2) Symptoms may occur in the vertebral facet joints of 15% to 40% of patients with lower back pain. (3) Medial branch radiofrequency neurotomy is a minimally invasive outpatient procedure that reduces pain by interrupting the nerve supply to painful facet joints. Read More

View Article

Download full-text PDF

Source
May 2006
3 Reads

Recombinant activated factor VII for bleeding in patients without inherited bleeding disorders.

Authors:
S Selin A Tejani

Issues Emerg Health Technol 2006 Mar(82):1-4

(1) Recombinant activated factor VII (rFVIIa) is licensed in Canada for the prevention and treatment of bleeding in hemophiliacs, but it is increasingly used to control bleeding in non-hemophilic patients during surgery, or during treatment for severe trauma or intracerebral hemorrhage (ICH). (2) In one clinical trial, there was a significant reduction in mortality among patients with ICH treated with rFVIIa. In another trial, administration of rFVIIa significantly reduced the number of trauma patients needing massive blood transfusions although there was no significant difference in mortality. Read More

View Article

Download full-text PDF

Source
March 2006
4 Reads

CYP450 genotyping for determining drug metabolizer status.

Issues Emerg Health Technol 2006 Mar(81):1-4

View Article

Download full-text PDF

Source
March 2006
2 Reads

Radiofrequency ablation in the treatment of kidney cancer.

Authors:
D Hailey

Issues Emerg Health Technol 2006 Feb(80):1-4

(1) The standard approach for the treatment of kidney (renal) cancer is radical or partial nephrectomy (removal of the kidney). (2) Radiofrequency ablation (RFA), a less invasive approach, is an option for the treatment of small tumours, and in cases where surgery is contraindicated. (3) Its safety and efficacy compare favourably with those of other approaches. Read More

View Article

Download full-text PDF

Source
February 2006
5 Reads

Intragastric balloons: a temporary treatment for obesity.

Authors:
C Allison

Issues Emerg Health Technol 2006 Jan(79):1-4

(1) Intragastric balloons are a temporary non-surgical obesity treatment that induces short-term weight loss by partially filling the stomach to achieve satiety and reduce food intake. (2) Moderate weight loss may be achieved if patients adhere to a weight-reduction program. Weight gain often recurs when the balloon is removed after six months. Read More

View Article

Download full-text PDF

Source
January 2006
21 Reads

Cerebral protection devices for use during carotid artery stenting.

Authors:
T Stafinski D Menon

Issues Emerg Health Technol 2005 Dec(78):1-6

(1) Cerebral protection devices offer a new approach to reducing the risk of stroke and death in patients undergoing carotid angioplasty with stenting (CAS). (2) Nine studies have examined the efficacy of cerebral protection devices, by comparing the incidence of procedure related stroke and death to that of CAS without protection, and to surgical endarterectomy. Few of the studies were of high quality. Read More

View Article

Download full-text PDF

Source
December 2005
4 Reads

Atrasentan for metastatic hormone refractory prostate cancer.

Authors:
G Murphy

Issues Emerg Health Technol 2005 Dec(77):1-4

(1) Atrasentan (Xinlay(R)) is an anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists. The orally administered drug is being studied in a subset of patients with advanced prostate cancer. (2) Phase II and III studies evaluating time to clinical and radiographic progression failed to demonstrate a significant benefit with atrasentan versus placebo. Read More

View Article

Download full-text PDF

Source
December 2005
3 Reads

Pegaptanib for neovascular age-related macular degeneration.

Authors:
D Maberley

Issues Emerg Health Technol 2005 Dec(76):1-4

(1) Neovascular (wet) age-related macular degeneration (AMD) results from the growth of abnormal blood vessels under the retina (choroidal neovascularization). Sudden and permanent vision loss occurs as these vessels grow, leak, bleed, and scar. (2) A human protein, vascular endothelial growth factor (VEGF), is implicated in the development of wet AMD. Read More

View Article

Download full-text PDF

Source
December 2005
2 Reads

Vaccines for prevention of human papillomavirus infection.

Issues Emerg Health Technol 2005 Dec(75):1-4

(1) High risk types of human papillomavirus (HPV) are the causal agents of cervical cancer. The prevention of HPV infection can reduce the incidence of this cancer. (2) Five phase II clinical trials have been published, and several large phase III trials are underway. Read More

View Article

Download full-text PDF

Source
December 2005
3 Reads

Exenatide for the treatment of type 2 diabetes mellitus.

Authors:
B Ruddock

Issues Emerg Health Technol 2005 Aug(71):1-4

Exenatide is a glucagon-like peptide-1 agonist. It is being investigated as an add-on therapy for patients with type 2 diabetes mellitus who are taking oral antidiabetic drugs. Evidence indicates that exenatide reduces glycosylated hemoglobin and plasma glucose levels when compared with placebo. Read More

View Article

Download full-text PDF

Source
August 2005
3 Reads

Roflumilast for asthma and chronic obstructive pulmonary disease.

Authors:
C Cowan

Issues Emerg Health Technol 2005 Oct(74):1-4

Roflumilast is an inhibitor of phosphodiesterase- IV (PDE4), a cellular enzyme that is linked to airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). In clinical trials, roflumilast produced significant improvements in FEV1 (forced expiratory volume in one second) and PEF (peak expiratory flow) compared with low-dose inhaled beclomethasone in asthma patients, and compared with placebo in COPD patients. Roflumilast reduced the use of rescue medication in both populations. Read More

View Article

Download full-text PDF

Source
October 2005
2 Reads

Abatacept as add-on therapy for rheumatoid arthritis.

Authors:
C Allison

Issues Emerg Health Technol 2005 Sep(73):1-4

Abatacept is a co-stimulation blocker that inhibits T-cell activation and interrupts the process leading to inflammation in rheumatoid arthritis. Patients with severe arthritis who took abatacept with at least one other disease-modifying antirheumatic drug in six and 12-month clinical trials demonstrated statistically significant improvement in tender, swollen joints and other clinical measures compared with placebo. Mild to moderate adverse events included headache, nasopharyngitis, hypertension and back pain. Read More

View Article

Download full-text PDF

Source
September 2005
4 Reads

Sativex for the management of multiple sclerosis symptoms.

Authors:
Perras C

Issues Emerg Health Technol 2005 Sep(72):1-4

Sativex (R) is a cannabis-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray. It has been approved as adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS). It is being investigated for the management of other MS symptoms, such as spasticity. Read More

View Article

Download full-text PDF

Source
September 2005
6 Reads

MRI-guided focused ultrasound treatment of uterine fibroids.

Authors:
S Chen

Issues Emerg Health Technol 2005 Jul(70):1-4

Magnetic resonance imaging-guided focused ultrasound (MRI-FUS) is a minimally invasive alternative to surgical and less invasive treatments for uterine fibroids. Early results from small sample studies indicate that the procedure may provide short-term symptom relief with advantages such as shorter recovery time. Few occurrences of major adverse events are reported. Read More

View Article

Download full-text PDF

Source
July 2005
4 Reads

Automated external defibrillators for home use.

Issues Emerg Health Technol 2005 Jun(69):1-4

The Philips HeartStart Home Defibrillator is an automated external defibrillator (AED) that is approved for home use by untrained users. Most cardiac arrests occur in the home, so a rapid response with cardiopulmonary resuscitation (CPR) and defibrillation is critical for survival. No prospective studies demonstrate that the use of AEDs in the home by untrained persons improves health outcomes. Read More

View Article

Download full-text PDF

Source
June 2005
4 Reads

Role of combination inhaled corticosteroids and long acting beta agonists in the treatment of adult asthma.

Issues Emerg Health Technol 2005 Jun(68):1-4

An inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) are combined in an inhaler for treatment of persistent asthma. There is evidence that maintenance therapy with a combination ICS/LABA inhaler improves clinical outcomes and reduces airflow obstruction in patients with persistent asthma, who are not well controlled even when using ICS maintenance therapy. There is evidence that a combination ICS/LABA inhaler may also play a role in initial maintenance therapy for patients with mild persistent asthma, who have never used ICS therapy. Read More

View Article

Download full-text PDF

Source
June 2005
2 Reads